Unique ID issued by UMIN | UMIN000040584 |
---|---|
Receipt number | R000046318 |
Scientific Title | A Prospective, Multicenter, Observational Study of the Efficacy and Safety of Corticosteroids for Tumor-Induced Central and Peripheral Neuropathic Pain in Cancer Patients. |
Date of disclosure of the study information | 2020/06/01 |
Last modified on | 2020/05/29 18:54:08 |
A Clinical Study of the Efficacy and Safety of Corticosteroids for Cancer-induced Neuropathic Pain.
A Clinical Study of the Efficacy and Safety of Corticosteroids for Cancer-induced Neuropathic Pain.
A Prospective, Multicenter, Observational Study of the Efficacy and Safety of Corticosteroids for Tumor-Induced Central and Peripheral Neuropathic Pain in Cancer Patients.
A Prospective Observational Study of the Efficacy and Safety of Corticosteroids for Tumor-Induced Neuropathic Pain.
Japan |
Cancer pain
Medicine in general | Anesthesiology | Adult |
Malignancy
NO
To evaluate the effectiveness and safety of systemic administration of corticosteroids for the treatment of cancer induced central and peripheral neuropathic pain.
Safety,Efficacy
To compare the difference of pain intensity (worst pain in 24 hours) between baseline, 72 hours later and 168 hours later.
Observational
20 | years-old | <= |
999 | years-old | > |
Male and Female
Patients over 20 years old
Patients who have been diagnosed with cancer.
Patients in the hospital
Patients with cancer pain (Brief Pain Inventory short form; worst pain intensity score of 4 or higher in the past 24 hours)
Patients will be scheduled to receive regular corticosteroids for the treatment of cancer-induced neuropathic pain
Patients whose physicians consider it inappropriate to participate in the research.
Patients who are pregnant, lactating, or may be pregnant.
Patients with diabetes who have poor glycemic control who need additional insulin injections
Patients with an infection-caused fever of 38 degrees or higher
Patients undergoing treatment for an active gastrointestinal ulcer
Patients with diagnoses of hematological malignancy
Serious adverse events due to corticosteroid in the past
Patients who started a new anticancer treatment with a molecularly targeted agency or immune checkpoint inhibitor within 2 weeks, or are scheduled to start the treatment within 1 week
Patients were administrated corticosteroids more than the scheduled dose on the day before the start of treatment
Patients scheduled to administrate corticosteroids more than its regular doses in one week for the treatment of adverse effects by anticancer therapy
Patients who are scheduled to receive surgery for the pain control in a week
200
1st name | Keita |
Middle name | |
Last name | Tagami |
Tohoku University Graduate School of Medicine
Palliative Medicine
9808575
2-1, Seiryo-machi, Aobaku, Sendai, Miyagi, 9808575, Japan
0227177366
keita.tagami.d7@tohoku.ac.jp
1st name | Keita |
Middle name | |
Last name | Tagami |
Tohoku University Graduate School of Medicine
Palliative Medicine
9808575
2-1, Seiryo-machi, Aobaku, Sendai, Miyagi, 9808575, Japan
0227177366
keita.tagami.d7@tohoku.ac.jp
Tohoku University Graduate School of Medicine
Japan Science and Technology Agency
Japanese Governmental office
Ethics Committee of the Graduate School of Medicine
2-1, Seiryo-machi, Aoba-ku, Sendai, Japan
0227178007
med-kenkyo@grp.tohoku.ac.jp
NO
2020 | Year | 06 | Month | 01 | Day |
Unpublished
Preinitiation
2020 | Year | 02 | Month | 03 | Day |
2020 | Year | 02 | Month | 17 | Day |
2020 | Year | 06 | Month | 01 | Day |
2021 | Year | 12 | Month | 31 | Day |
Prospective Observational Study
The patients who admit in the hospital from June 6 2020 to December 31 2021 are registered.
2020 | Year | 05 | Month | 29 | Day |
2020 | Year | 05 | Month | 29 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046318